Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
Ji Won Han, Seung Kew Yoon
Pharmaceutics (2021) Vol. 13, Iss. 9, pp. 1387-1387
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Immunotherapies for hepatocellular carcinoma
Justin K. H. Liu, Andrew F. Irvine, Rebecca Jones, et al.
Cancer Medicine (2021) Vol. 11, Iss. 3, pp. 571-591
Open Access | Times Cited: 63
Rational Nanomedicine Design Enhances Clinically Physical Treatment‐Inspired or Combined Immunotherapy
Qiaoqiao Liu, Wei Zhang, Rong Jiao, et al.
Advanced Science (2022) Vol. 9, Iss. 29
Open Access | Times Cited: 40
The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
Nicolò Brandi, Matteo Renzulli
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8598-8598
Open Access | Times Cited: 18
Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
Shuling Chen, Xuezhen Zeng, Tianhong Su, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy
Roma Raj, Chase J. Wehrle, Nihal Aykun, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5220-5220
Open Access | Times Cited: 13
Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review
Gui-Lin Xie, Zhi-Han Zhong, Tai‐Wei Ye, et al.
BMC Surgery (2025) Vol. 25, Iss. 1
Open Access
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
Chengxiang Guo, Weibo Du, Yiwen Chen, et al.
Cancer Medicine (2025) Vol. 14, Iss. 3
Open Access
Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate
Gabriel Fridolin Hess, Caner Ercan, Alexander Wilhelm, et al.
Pathobiology (2025), pp. 1-12
Open Access
A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma
Yu Rim Lee
Journal of Liver Cancer (2023) Vol. 23, Iss. 2, pp. 316-329
Open Access | Times Cited: 10
Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma
Lu Sun, Jun Qi, Lei Ding, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future
Qizheng Dai, Bo Cao, Shiqing Zhao, et al.
Bioengineering (2022) Vol. 9, Iss. 9, pp. 474-474
Open Access | Times Cited: 13
TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
Bufu Tang, Yajie Wang, Jinyu Zhu, et al.
Biological Procedures Online (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Predictive value of circulating immune cell changes in response to PD-1 blockade and TKI therapy in patients with hepatocellular carcinoma
Jianpeng Wang, Ping Xiao, Xishan Li, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102390-102390
Closed Access | Times Cited: 2
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Tong Liu, Guorui Meng, Shihui Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation
Qingqing Liu, Hui-Zhou Li, Shu-Xian Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 8, pp. 167493-167493
Closed Access | Times Cited: 2
Immunotherapy for advanced or recurrent hepatocellular carcinoma
Ying-Zhe Luo, Hong Zhu
World Journal of Gastrointestinal Oncology (2023) Vol. 15, Iss. 3, pp. 405-424
Open Access | Times Cited: 5
Immunotherapy for Advanced Hepatocellular Carcinoma-a Large Tertiary Center Experience
Roma Raj, Nihal Aykun, Chase J. Wehrle, et al.
Journal of Gastrointestinal Surgery (2023) Vol. 27, Iss. 10, pp. 2126-2134
Closed Access | Times Cited: 5
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma
Ji Hong Kim, Young Il Kim, Heechul Nam, et al.
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access | Times Cited: 1
Dynamic peripheral T-cell analysis identifies on-treatment prognostic biomarkers of atezolizumab plus bevacizumab in hepatocellular carcinoma
Ji Won Han, Min Woo Kang, Soon Kyu Lee, et al.
Liver Cancer (2024), pp. 1-13
Open Access | Times Cited: 1
Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
Ji Won Han, Ji Hoon Kim, Dong Hyun Kim, et al.
Diagnostics (2023) Vol. 13, Iss. 8, pp. 1453-1453
Open Access | Times Cited: 3
The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients
Xiaochen Ma, Xiangyang Sun, Fubo Xie, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 619-628
Open Access
Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Young Mi Hong
European Journal of Gastroenterology & Hepatology (2024)
Closed Access
TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report
Bin Guo, Yi Zhou, Zhicheng Liu, et al.
Clinics and Research in Hepatology and Gastroenterology (2023) Vol. 47, Iss. 7, pp. 102169-102169
Open Access | Times Cited: 1
Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
Qin Shi, Peng Huang, Zihan Zhang, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1861-1871
Open Access | Times Cited: 1
Transient Cytolysis after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Manuel Rodríguez‐Perálvarez
Journal of Personalized Medicine (2022) Vol. 12, Iss. 10, pp. 1663-1663
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top